Engineered PD1-IL15 Improves Intratumoral CD8+ T cell Function and Antitumor Immunity
Time: 9:00 am
day: Conference Day One
Details:
- Designing PD1-IL15 to deliver stimulation to PD1+ tumor-infiltrating lymphocytes (TIL) while minimally affecting circulating peripheral natural killer (NK) cells and T cells
- The PD1-IL15 mouse surrogate promotes CD8 T cell-dependent anti-tumor Immunity
- Enhancing efficacy compared to the combination of aPD1 with an IL-15 Superagonist
